Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.03. | RxSight (NASDAQ:RXST) Sets New 12-Month Low Following Analyst Downgrade | 1 | MarketBeat | ||
21.03. | BofA cuts RxSight stock price target to $36, maintains Buy rating | 2 | Investing.com | ||
19.03. | The Analyst Verdict: RxSight In The Eyes Of 9 Experts | 2 | Benzinga.com | ||
RXSIGHT Aktie jetzt für 0€ handeln | |||||
19.03. | Stifel cuts RxSight stock price target to $28 from $33 | 3 | Investing.com | ||
26.02. | Expert Outlook: RxSight Through The Eyes Of 11 Analysts | 3 | Benzinga.com | ||
26.02. | Jefferies cuts RxSight stock price target to $50, maintains Buy rating | 2 | Investing.com | ||
25.02. | RxSight, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | RxSight, Inc. - 10-K, Annual Report | - | SEC Filings | ||
18.02. | Stifel maintains hold on RxSight shares, target at $35.00 | 1 | Investing.com | ||
15.02. | RxSight (NASDAQ:RXST) Trading Down 4.7% - Should You Sell? | 2 | MarketBeat | ||
11.02. | RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025 | 2 | GlobeNewswire (USA) | ||
27.01. | RxSight-Direktorin verkauft Stammaktien im Wert von 108.618 US-Dollar | - | Investing.com Deutsch | ||
13.01. | RxSight (NASDAQ:RXST) Given New $40.00 Price Target at Wells Fargo & Company | 3 | MarketBeat | ||
13.01. | RxSight-Aktien brechen um 21% ein nach enttäuschender Umsatzprognose | 2 | Investing.com Deutsch | ||
13.01. | RxSight shares drop by 21% following disappointing revenue forecast | 1 | Investing.com | ||
12.01. | RxSight Projects 41% Revenue Growth For Q4 | - | RTTNews | ||
12.01. | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | 181 | GlobeNewswire (Europe) | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
20.12.24 | RxSight cut to hold at Stifel on competition concerns | 4 | Seeking Alpha | ||
20.12.24 | Do You Believe in the Long-Term Growth Potential of RxSight (RXST)? | 4 | Insider Monkey | ||
20.12.24 | Forecasting The Future: 4 Analyst Projections For RxSight | 2 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 55,55 | 0,00 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Vereinbarung/Auftragseingänge
Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm... ► Artikel lesen | |
HIMS & HERS HEALTH | 29,090 | +6,40 % | Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound | ||
RESMED | 205,70 | -0,63 % | Aktienmarkt: Kurs der ResMed-Aktie im Plus (207,3681 €) | Im Plus liegt derzeit der Anteilsschein von ResMed . Der jüngste Kurs betrug 224,14 US-Dollar. Heute hat sich im US-amerikanischen Wertpapierhandel die ResMed-Aktie zwischenzeitlich um 1,02 Prozent... ► Artikel lesen | |
SENSEONICS | 0,600 | -1,54 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results | Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial partner, Ascensia Patient base increased 56% in 2024 over 2023 to approximately... ► Artikel lesen | |
BONESUPPORT | 29,000 | +6,46 % | Bonesupport Holding Aktie: Willkommen zur Erfolgsgeschichte! | Die Bonesupport Holding Aktie verzeichnete am 22. März einen erfreulichen Tagesgewinn von 1,61% und schloss bei 30,25 EUR. Dies stellt eine positive Entwicklung dar, obwohl das Orthobiologie-Unternehmen... ► Artikel lesen | |
LANTHEUS | 90,14 | -0,16 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
TRANSMEDICS GROUP | 63,78 | +2,54 % | Jim Cramer Finds TransMedics Group, Inc. (TMDX) Interesting but Expensive - Caution Advised! | ||
INSPIRE MEDICAL SYSTEMS | 144,00 | -2,34 % | Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook | MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally... ► Artikel lesen | |
ALPHATEC | 9,150 | +0,55 % | Alphatec Holdings, Inc. Announces Select Preliminary Financial Results for 2024 and Provides 2025 Outlook | CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today preliminary... ► Artikel lesen | |
JOINT CORP | 12,190 | -2,95 % | The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results | - Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 - SCOTTSDALE, Ariz.,... ► Artikel lesen | |
CHEMOMETEC | 66,70 | -0,07 % | Chemometec A/S: Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings | ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue... ► Artikel lesen | |
OPTIMIZERX | 8,055 | -6,77 % | OptimizeRx Corporation: OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results | Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 50,12 | +1,03 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum zweiten Quartal auf "Buy" mit einem Kursziel von 65 Euro belassen. Die Geschäfte in... ► Artikel lesen | |
FRESENIUS | 39,480 | +0,28 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Fresenius von 40 auf 47 Euro angehoben und die Einstufung auf "Buy" belassen. Der Fokus der Bad Homburger liege inzwischen... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 45,880 | +0,53 % | Fresenius Medical Care Aktie: Stabile Wachstumstrends fortgesetzt | Der Dialysespezialist konsolidiert seine Position mit 1,4-prozentigem Zuwachs auf 45,65 Euro und signalisiert bemerkenswerte Erholung vom 52-Wochen-Tiefstand Die Aktie von Fresenius Medical Care (FMC)... ► Artikel lesen |